IP Library Granted Patent US 10,806,728
Granted Patent B2
US 10,806,728 · App. 16/672,714 · Granted Oct 20, 2020

Pharmaceutical salts of isomyosmine and pharmaceutical compositions containing same

Inventor: Jonnie R. Williams (Sarasota, FL)
Assignee: MyMD Pharmaceuticals, Inc.
A61K31/465A61K8/4926A61K31/4439A61P3/08C07K14/4747Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,728
App. No.
16/672,714
Granted
Oct 20, 2020
Kind
B2
Abstract

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).

Claims (20)

1. A pharmaceutical salt of isomyosmine wherein the salt is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethane sulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid (L), aspartic acid (L), benzenesulfonic acid, benzoic acid, camphoric acid (+), camphor-10-sulfonic acid (+), capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid (D), gluconic acid (D), glucuronic acid (D), glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid (DL), lactobionic acid, lauric acid, maleic acid, malic acid (−L), malonic acid, mandelic acid (DL), methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid (−L), salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid (+L), thiocyanic acid, toluenesulfonic acid (p), and undecylenic acid.

2. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethane sulfonic acid, and 2-oxoglutaric acid.

3. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, and adipic acid.

4. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of ascorbic acid (L), aspartic acid (L), benzenesulfonic acid, and benzoic acid.

5. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of camphoric acid (+), camphor-10-sulfonic acid (+), capric acid (decanoic acid), and caproic acid (hexanoic acid).

6. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of caprylic acid (octanoic acid), carbonic acid, cinnamic acid, and citric acid.

7. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, and ethanesulfonic acid.

8. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of formic acid, fumaric acid, galactaric acid, and gentisic acid.

9. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of glucoheptonic acid (D), gluconic acid (D), glucuronic acid (D), and glutamic acid.

10. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of glutaric acid, glycerophosphoric acid, glycolic acid, and hippuric acid.

11. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of hydrobromic acid, isobutyric acid, lactic acid (DL), and lactobionic acid.

12. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of lauric acid, maleic acid, malic acid (−L), and malonic acid.

13. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of mandelic acid (DL), methanesulfonic acid, naphthalene-1,5-disulfonic acid, and naphthalene-2-sulfonic acid.

14. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of nicotinic acid, nitric acid, oleic acid, and oxalic acid.

15. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of palmitic acid, pamoic acid, phosphoric acid, and proprionic acid.

16. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of pyroglutamic acid (−L), salicylic acid, sebacic acid, stearic acid, and succinic acid.

17. The pharmaceutical salt of claim 1 wherein the salt is selected from the group consisting of sulfuric acid, tartaric acid (+L), thiocyanic acid, toluenesulfonic acid (p), and undecylenic acid.

18. A pharmaceutical composition comprising the pharmaceutical salt of claim 1 and a pharmaceutically acceptable carrier.

19. Isomyosmine hydrochloride.

20. A pharmaceutical composition comprising isomyosmine hydrochloride of claim 19 and a pharmaceutically acceptable carrier.

Assignments (4)
CHANGE OF NAME Recorded Jun 10, 2025
From: MYMD PHARMACEUTICALS, INC.
To: TNF PHARMACEUTICALS, INC.
Reel/Frame 071501/0834 →
MERGER Recorded Apr 22, 2022
From: MYMD PHARMACEUTICALS (FLORIDA), INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 059680/0941 →
CHANGE OF NAME Recorded Jun 25, 2021
From: MYMD PHARMACEUTICALS, INC.
To: MYMD PHARMACEUTICALS (FLORIDA), INC.
Reel/Frame 056670/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2019
From: WILLIAMS, JONNIE R.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 050907/0009 →
Continuity (3)
Division 15558094
Provisional Application 62140618 · Mar 31, 2015
Related Publication 20200061043A1 · Feb 27, 2020
Cited By (1)
US 12,357,625